Chikungunya fever in travelers: clinical presentation and course.

Standard

Chikungunya fever in travelers: clinical presentation and course. / Taubitz, Winfried; Cramer, Jakob; Kapaun, Anette; Pfeffer, Martin; Drosten, Christian; Dobler, Gerhard; Burchard, Gerd-Dieter; Löscher, Thomas.

In: CLIN INFECT DIS, Vol. 45, No. 1, 1, 2007, p. 1-4.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Taubitz, W, Cramer, J, Kapaun, A, Pfeffer, M, Drosten, C, Dobler, G, Burchard, G-D & Löscher, T 2007, 'Chikungunya fever in travelers: clinical presentation and course.', CLIN INFECT DIS, vol. 45, no. 1, 1, pp. 1-4. <http://www.ncbi.nlm.nih.gov/pubmed/17554689?dopt=Citation>

APA

Taubitz, W., Cramer, J., Kapaun, A., Pfeffer, M., Drosten, C., Dobler, G., Burchard, G-D., & Löscher, T. (2007). Chikungunya fever in travelers: clinical presentation and course. CLIN INFECT DIS, 45(1), 1-4. [1]. http://www.ncbi.nlm.nih.gov/pubmed/17554689?dopt=Citation

Vancouver

Taubitz W, Cramer J, Kapaun A, Pfeffer M, Drosten C, Dobler G et al. Chikungunya fever in travelers: clinical presentation and course. CLIN INFECT DIS. 2007;45(1):1-4. 1.

Bibtex

@article{763e4b03ef174d6cb4e80ae290845ea3,
title = "Chikungunya fever in travelers: clinical presentation and course.",
abstract = "BACKGROUND: An outbreak of chikungunya virus infection emerged in the southwest Indian Ocean islands in 2005, spread out to India, and resulted in an ongoing outbreak that has involved >1.5 million patients, including travelers who have visited these areas. METHODS: Our study investigated 69 travelers who developed signs and symptoms compatible with chikungunya fever after returning home from countries involved in the epidemic. Twenty cases of infection that were confirmed by serological analysis, polymerase chain reaction, and/or cell culture were investigated. RESULTS: All patients experienced flulike symptoms with fever and joint pain. No serious complications were observed, but 69% of the patients had persistent arthralgia for >2 months, and 13% had it for >6 months. Viral RNA could be detected in blood samples using reverse-transcriptase polymerase chain reaction in 4 of 4 patients who presented to a health care facility during their first week of illness, and the virus was successfully isolated from blood samples obtained from 2 of these patients. Chikungunya virus-specific immunoglobulin M and/or immunoglobulin G antibodies were detected in all patients. However, initial testing of serum samples yielded negative results for 3 of 5 patients during the first week. CONCLUSIONS: Chikungunya fever must be considered in travelers who develop fever and arthritis after traveling to areas affected by an ongoing epidemic. Related arthritis mainly affects smaller joints and often persists for extended periods. Serological testing may have negative results during the first week of the disease; diagnosis using polymerase chain reaction appears to be more reliable during this time. Travelers to areas of epidemicity should be informed of the risk of infection and of adequate preventive measures, such as protection against mosquitos.",
author = "Winfried Taubitz and Jakob Cramer and Anette Kapaun and Martin Pfeffer and Christian Drosten and Gerhard Dobler and Gerd-Dieter Burchard and Thomas L{\"o}scher",
year = "2007",
language = "Deutsch",
volume = "45",
pages = "1--4",
journal = "CLIN INFECT DIS",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Chikungunya fever in travelers: clinical presentation and course.

AU - Taubitz, Winfried

AU - Cramer, Jakob

AU - Kapaun, Anette

AU - Pfeffer, Martin

AU - Drosten, Christian

AU - Dobler, Gerhard

AU - Burchard, Gerd-Dieter

AU - Löscher, Thomas

PY - 2007

Y1 - 2007

N2 - BACKGROUND: An outbreak of chikungunya virus infection emerged in the southwest Indian Ocean islands in 2005, spread out to India, and resulted in an ongoing outbreak that has involved >1.5 million patients, including travelers who have visited these areas. METHODS: Our study investigated 69 travelers who developed signs and symptoms compatible with chikungunya fever after returning home from countries involved in the epidemic. Twenty cases of infection that were confirmed by serological analysis, polymerase chain reaction, and/or cell culture were investigated. RESULTS: All patients experienced flulike symptoms with fever and joint pain. No serious complications were observed, but 69% of the patients had persistent arthralgia for >2 months, and 13% had it for >6 months. Viral RNA could be detected in blood samples using reverse-transcriptase polymerase chain reaction in 4 of 4 patients who presented to a health care facility during their first week of illness, and the virus was successfully isolated from blood samples obtained from 2 of these patients. Chikungunya virus-specific immunoglobulin M and/or immunoglobulin G antibodies were detected in all patients. However, initial testing of serum samples yielded negative results for 3 of 5 patients during the first week. CONCLUSIONS: Chikungunya fever must be considered in travelers who develop fever and arthritis after traveling to areas affected by an ongoing epidemic. Related arthritis mainly affects smaller joints and often persists for extended periods. Serological testing may have negative results during the first week of the disease; diagnosis using polymerase chain reaction appears to be more reliable during this time. Travelers to areas of epidemicity should be informed of the risk of infection and of adequate preventive measures, such as protection against mosquitos.

AB - BACKGROUND: An outbreak of chikungunya virus infection emerged in the southwest Indian Ocean islands in 2005, spread out to India, and resulted in an ongoing outbreak that has involved >1.5 million patients, including travelers who have visited these areas. METHODS: Our study investigated 69 travelers who developed signs and symptoms compatible with chikungunya fever after returning home from countries involved in the epidemic. Twenty cases of infection that were confirmed by serological analysis, polymerase chain reaction, and/or cell culture were investigated. RESULTS: All patients experienced flulike symptoms with fever and joint pain. No serious complications were observed, but 69% of the patients had persistent arthralgia for >2 months, and 13% had it for >6 months. Viral RNA could be detected in blood samples using reverse-transcriptase polymerase chain reaction in 4 of 4 patients who presented to a health care facility during their first week of illness, and the virus was successfully isolated from blood samples obtained from 2 of these patients. Chikungunya virus-specific immunoglobulin M and/or immunoglobulin G antibodies were detected in all patients. However, initial testing of serum samples yielded negative results for 3 of 5 patients during the first week. CONCLUSIONS: Chikungunya fever must be considered in travelers who develop fever and arthritis after traveling to areas affected by an ongoing epidemic. Related arthritis mainly affects smaller joints and often persists for extended periods. Serological testing may have negative results during the first week of the disease; diagnosis using polymerase chain reaction appears to be more reliable during this time. Travelers to areas of epidemicity should be informed of the risk of infection and of adequate preventive measures, such as protection against mosquitos.

M3 - SCORING: Zeitschriftenaufsatz

VL - 45

SP - 1

EP - 4

JO - CLIN INFECT DIS

JF - CLIN INFECT DIS

SN - 1058-4838

IS - 1

M1 - 1

ER -